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Abstract
The development of oncology drugs progresses through multiple phases, where after
each phase a decision is made about whether to move a molecule forward. Early phase
efficacy decisions are often made on the basis of single arm studies based on RECIST tumor
response as endpoint. This decision rules are implicitly assuming some form of surrogacy
between tumor response and long-term endpoints like progression-free survival (PFS) or
overall survival (OS). The surrogacy is most often assessed as weak, but sufficient to allow
a rapid decision making as early phase studies lack the survival follow up and number
of patients to properly assess PFS or OS. With the emergence of therapies with new
mechanisms of action, for which the link between RECIST tumor response and long-term
endpoints is either not accessible yet because not enough data is available to perform a
meta-regression, or the link is weaker than with classical chemotherapies, tumor response
based rules may not be optimal. In this paper, we explore the use of a multistate model
for decision making based on single-arm early phase trials. The multistate model allows to
account for more information than the simple RECIST response status, namely, the time
to get to response, the duration of response, the PFS time and time to death. We propose
to base the decision on efficacy on the OS hazard ratio (HR), predicted from a multistate
model based on early phase data with limited survival follow-up, combined with historical
control data. Using three case studies and simulations, we illustrate the feasibility of the
estimation of the OS HR using a multistate model based on limited data from early phase
studies. We argue that, in the presence of limited follow up and small sample size, and on
assumptions within the multistate model, the OS prediction is acceptable and may lead
to better decisions for continuing the development of a drug.
Keywords: Multistate Model, Clinical Trial, Decision Making.
1. Introduction
In pharmaceutical oncology drug development, single-arm trials are often used in early phase
to gather the first evidence of a new molecule’s efficacy, with drug activity determined through
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2 Multistate models for early decision making
tumour response using the RECIST criterion (Brown, Gregory, Twelves, Buyse, Collinson,
Parmar, Seymour, and Brown 2011; Grayling and Mander 2016). The observed complete
response proportion (CR), overall response proportion (OR), defined as CR + partial respon-
ders, or disease control proportion (DC) defined as OR + stable disease patients, is compared
to a benchmark based on historical control data. A decision is then made whether to advance
the molecule into pivotal randomized clinical trial testing, or Phase 3. The implicit assumption
for this gating approach is, that the measures evaluated at the end of the early development
phase are good surrogates for the primary endpoint in Phase 3, either progression-free (PFS)
or overall survival (OS). Such surrogacy is generally assessed through meta-analytic methods
(Buyse, Molenberghs, Burzykowski, Renard, and Geys 2000), but in many indications consid-
ered to be moderate to poor (Fiteni and Bonnetain 2016; Nakashima, Horita, Nagai, Manabe,
Murakami, Ota, and Kaneko 2016; Kemp and Prasad 2017).
With the advent of immunotherapy in oncology, surrogacy associations between response and
OS are further complicated by three aspects: First, in many indications there is only very
limited data available yet, and/or OS data is not mature enough, to explore the association
between effect measures on a trial level. Second, the immunotherapy mechanism of action
(MoA) insinuates that the association between a response-based endpoint and OS might be
different from previous chemo- or targeted-therapy based agents. Mushti, Mulkey, and Srid-
hara (2018) provide an early analysis of 13 studies on a new class of agent in five indications.
Their conclusion is, that responders exhibited longer survival and PFS than non-responders,
but that the trial- and individual level associations were weak between ORR or PFS and OS.
Note that the statement about the longer OS for responders might potentially be prone to
immortal bias (Weber, Wolkewitz, and Schumacher 2018). Third, immunotherapy leads to a
delayed effect of the therapy on PFS or OS (Hoos 2012; Chen 2013). These papers highlight
the challenges of the classical response and OS analysis linked to the delayed effect of the im-
munotherapies. The consequences of the delayed effect are that response patterns are different
and that OS shows a non-proportional ratio when compared to classical chemotherapies.
The immunotherapy MoA suggests that compared to standard chemo- or targeted therapy,
immunotherapy potentially acts by not only increasing the proportion of responders, but
also prolonging response duration (duration of response, DOR) for responding patients and
post-progression survival, potentially implying increased OS. Taken together with the weak
surrogacy association in general, this raises the question of whether gating criteria in early
decision making in drug development can be improved by considering more granular infor-
mation. Ideally, one would like to decide on whether to advance a molecule in Phase 3 not
only based on comparing the estimated response proportion in a cohort treated with the new
drug to an estimated proportion received from a historical control cohort, but get an unbiased
estimate of the OS survival function for the new molecule.
Now, early phase trials generally are neither large enough nor do they have long follow-up.
As a consequence, little information on OS can be collected directly from the trial. Instead
of estimation from data, one thus needs to predict the OS survival function. In this paper,
we propose to compute such a prediction via a multistate model that borrows estimates of
transition hazards from another trial in the same population. This prediction of the survival
function in the experimental arm can then be benchmarked to n estimate of the survival
function based on the control. The latter is generally available from previous trials and/or
historical data. Based on this comparison, operating characteristics of a potential Phase 3 trial
of the new molecule can then be explored, and these can be compared to their counterparts
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based on response only.
In this multistate model, transition hazards and probabilities can either be estimated based
on the already available data from the early phase trial of the new molecule itself, or (some
of them) can be borrowed from the historical control trial, under plausible assumptions.
Since in a first step, our aim is to explore the general feasibility of this approach, we will
put the concept to test by predicting OS based on early phase information retrospectively in
three randomized Phase 3 clinical trials (RCT) in three different disease indications (breast,
bladder, and non-small cell lung cancer). In these RCTs, artificially administratively censored
data in the experimental arm reflects early phase data from the new molecule, and the entire
control arm data corresponds to the historical control. After fitting a multistate model, we
explore operating characteristics as a function of an assumed gating value of the OS hazard
ratio. Furthermore, we provide a recommendation on the minimal survival follow-up necessary
to obtain a robust estimate of the multistate model to support robust decision-making.
Usually, the clinical relevance of a difference in response proportions is only indirectly accessi-
ble at best, e.g. through meta-analyses. Having a reliable OS prediction for the new molecule
also enables to compute an effect measure, the OS HR, that is relevant for how the patient
feels, functions, and survives (Temple 1995).
The proposed setup of taking the historical control data from the control arm of an RCT
provides an idealized situation to test our multistate model on, since it avoids issues with
both, selection and calendar time bias. For a new general gating approach to be valid at
all it has to work in this ideal scenario. A discussion of how to potentially address the bias
questions is provided in Section 7.
This paper is structured as follows: In Section 2, we describe our motivating examples that
highlight the challenges posed by classical decision making. In Section 3, we introduce the
proposed multistate model whereas in Section 4, we illustrate the feasibility of the proposed
approach under the assumption that post-progression information can be borrowed from his-
torical data. In Section 5, we illustrate the feasibility of the proposed approach using a less
restrictive assumption. We end this paper by a summary and conclusion in Section 7.
2. Case studies
In this section we briefly describe the three RCTs from which we will use the data to develop
the multistate approach.
2.1. Cleopatra trial: New antibody as add on to chemotherapy
Cleopatra was a Phase 3 RCT which compared Docetaxel + Trastuzumab + Pertuzumab
(experimental treatment) against Docetaxel + Trastuzumab + Placebo (control treatment)
in 808 previously untreated HER2-positive metastatic breast cancer patients using a pri-
mary endpoint of independently-assessed PFS (Baselga, Cortes, Kim, Im, Hegg, Im, Roman,
Pedrini, Pienkowski, Knott, Clark, Benyunes, Ross, Swain, Bartoli, Bianconi, Kotliar, La-
cava, Matwiejuk, Price, Varela, Andrade, Araujo, Azevedo, Cortes, Costa e Silva, Cubero,
Delgado, Diz, Eyll, Franke, Hegg, Ismael, Jendiroba, Pedrini, Pereira, Pinczowski, Tokunaga,
Tosello, Brezden-Masley, Cheng, Ouyang, Shen, Wang, Wang, Yau, Yeo, Otero, Soldic, Vr-
banec, Soria, Kellokumpu-Lehtinen, Pyrhonen, Campone, Coudert, Ferrero, Priou, Aktas,
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Aulitzky, Clemens, Grischke, Hauschild, Just, Kirsch, Kuemmel, Maintz, Marme, Mueller,
Schmidt, Schneeweiss, Schumacher, Thomssen, Wesenberg, Castro-Salguero, Hernandez Mon-
roy, Zelina-Toache, Amadori, Angiolini, Biganzoli, Cinieri, Gamucci, Iacobelli, Latini, Mon-
temurro, Simoncini, Aogi, Fuji, Horiguchi, Inoue, Ito, Iwata, Kashiwaba, Kohno, Kuroi, Ma-
suda, Nakagami, Nakayama, Nishimura, Saji, Sasaki, Sato, Takeda, Tokuda, Tsugawa, Ueno,
Watanabe, Yoshiaki, Im, Im, Kim, Moon, Ro, Sohn, Grincuka, Kudaba, Purkalne, Kostovska-
Maneva, Stefanovski, Martinez, Tellez, Caguioa, Chan, Tudtud, Foszczynska-Kloda, Pienkowski,
Polkowski, Starows?awska, Tomczak, Gorbunova, Gotovkin, Kiselev, Kopp, Lichinitser, Merkulov,
Roman, Semiglazov, Shirinkin, Lee, Wong, Alba Conejo, Baselga, Batista, Calvo, Ciru-
elos, Cortes, Gil i Gil, Gonzalez, Hornedo Muguiro, Morales, Ribelles Entrena, Sanchez,
Sanchez Rovira, Arpornwirat, Dejthevaporn, Maneechavakajorn, Srimuninnimit, Sriuran-
pong, Sunpaweravong, Ahmad, Assersohn, Boiangiu, Davidson, Gallagher, Jones, Miles,
O’Reilly, Robinson, Wheatley, Agajanian, Armor, Audeh, Behairy, Birhiray, Blachly, Black-
well, Blanchard, Blanchet, Bowers, Brufsky, Budde, Carroll, Charu, Dakhil, Daniel, Ellerton,
Fehrenbacher, Flynn, Franco, Green, Hansen, Hargis, Hendricks, Hermann, Kallab, Karwal,
Kato, Kaufman, Kennedy, Klein, Lester, Lobo, Michaelson, Neidhart, Neidhart, Nguyen,
O’Rourke, Patel, Patel, Perez, Quackenbush, Peterson, Polikoff, Prill, Robles, Rodriguez,
Senecal, Sharma, Smith, Spicer, Swain, Taguchi, Vogel, Waterhouse, Yadav, and Yardley
2012). Here, Docetaxel is a chemotherapy and Trastuzumab a targeted-therapy agent with
an antibody dependent cellular cytotoxicity (ADCC) mode of action. As soon as progression
was diagnosed for a patient, treatment was stopped, in both arms. At the primary cutoff, in
the intention-to-treat (ITT) population, the combination arm prolonged PFS (hazard ratio,
HR = 0.62, 95% confidence interval, CI, from 0.51 to 0.75), OS (HR = 0.64, 95% CI from 0.47
to 0.88), and increased the proportion of responders by 0.108 from 0.693 to 0.802. In a follow-
up analysis (Swain, Baselga, Kim, Ro, Semiglazov, Campone, Ciruelos, Ferrero, Schneeweiss,
Heeson et al. 2015), prolongation of median DOR by 7.7 months was also reported.
2.2. Imvigor211 trial: Immuno- versus chemotherapy
Another Phase 3 RCT, Imvigor211, compared Atezolizumab (experimental treatment) against
chemotherapy (control treatment) in patients with platinum-treated locally advanced or metastatic
urothelial carcinoma (Powles, Dura´n, van der Heijden, Loriot, Vogelzang, De Giorgi, Oudard,
Retz, Castellano, Bamias et al. 2017). Atezolizumab is a cancer immunotherapy. In this trial,
treating patients post-progression in the Atezolizumab arm was allowed, but not mandatory.
The decision whether to continue treatment was at the discretion of the investigator. In the
ITT population, this trial showed an overall benefit in OS (HR = 0.84, 95% CI from 0.72
to 0.97). Note that the OS survival functions crossed and Atezolizumab benefit was only
seen after approximately 7 months. Neither response proportion nor PFS showed a benefit
in favor of Atezolizumab, even more progressors were reported in the Atezolizumab group.
However, in the responding patients, DOR was prolonged from a median of 7.4 months in the
chemotherapy to 21.7 months in the Atezolizumab arm.
2.3. Oak trial: Immuno- versus chemotherapy
Finally, Oak was another Phase 3 RCT comparing Atezolizumab (experimental treatment)
versus Docetaxel (control treatment) in patients with previously treated non-small-cell lung
cancer (Rittmeyer, Barlesi, Waterkamp, Park, Ciardiello, Von Pawel, Gadgeel, Hida, Kowal-
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ski, Dols et al. 2017). Similar to Imvigor211, post-progression treatment was allowed in the
Ateolizumab arm. Results were also comparable to Imvigor211: In the ITT population, an
OS HR of 0.73 (95% CI from 0.62 to 0.87) was observed, with no benefit for either response
or PFS. As in Imvigor211, DOR was prolonged in the Atezolizumab arm with a median of 16
months versus 6.2 months in the Docetaxel arm.
Tables 4-8 in the appendix provide a detailed summary of the results of the three case studies.
The Imvigor211 and Oak trials illustrate the difficulty of making early drug development
decisions based on response proportions when ultimately in Phase 3, a long-term endpoint
such as OS is assessed. In both trials, response proportions comparing arms were virtually
identical, but the OS HR point estimate and upper limit of a 95% confidence interval was
below 1.
3. Methods
3.1. Multistate models in general
Classical survival analysis focuses on the time from some time origin until the occurrence of an
event of interest, a quantity typically denoted survival or failure time (Beyersmann, Allignol,
and Schumacher 2012). Further events prior to the event of interest may substantially change
the risk of the event of interest to occur, e.g. response or progression may change the risk
of death in an oncology setting. If collected, such intermediate events provide more detailed
information on the disease process and allow for more precision in predicting the event-time
of a patient. Multistate models provide a framework that allow for the analysis of such event
history data. Figure 1 provides an example of a multistate model that connects the three
canonical oncology endpoints, namely response, progression, and death. In total, in this model
six transitions are possible.
For a detailed introduction into multistate models we refer to standard references such as
Putter, Fiocco, and Geskus (2007), Andersen and Pohar Perme (2008), Aalen, Borgan, and
Gjessing (2008), or Beyersmann et al. (2012). Here, we only give a very brief description
to allow definition of the quantities relevant for this paper. Let (Xt)t≥0 denote a stochastic
process with state space {1, . . . , J}, where Xt denotes the state an individual is in at time t.
Events are then modelled as transitions between the states of the model, so a progression out
of the initial SD state in Figure 1 would be modelled as a 1 → 3 transition. A key quantity
in multistate modelling are transition probabilities, defined as
Pij(s, t) := P (Xt = j|Xs = i,Past), s ≤ t.
The quantity Pij(s, t) denotes the probability to be in state i at time s and in state j at time
t, where Past is a σ-algebra generated by the process X up to time s, or more informally
the accumulated knowledge about the process’ history up to s. A transition hazard, i.e. the
instantaneous risk to move from state i to j at time t, is defined as
λij(t) · dt := P (X(t+dt)− = j|Xt− = i), i, j ∈ 1, 2, ..., J, i 6= j, (1)
and the corresponding cumulative transition hazard by
Λij(t) =
∫ t
0
λij(s)ds.
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In what follows we will assume X to be Markov. This assumption appears sensible in our
specific oncology application, since a patient with an early tumor progression will likely have
a different subsequent risk to die compared to a patient being progression-free for a longer
period.
3.2. OS prediction in a four-state oncology multistate model
In Sections 4 and 5 we will use a multistate model to make OS predictions. The model is
depicted in Figure 1 and consists of four states: patients enter having stable disease (State 1,
SD). Out of this initial state, after receiving treatment, they can either respond (Response,
State 2), progress (PD, State 3), or die without observed response or progression (Death,
State 4). Patients responding can either progress or die, and patients who progressed remain
at the risk of dying, i.e. a 3→ 4 transition.
Figure 1: Oncology multistate model used for OS predictions.
λ24(t)
λ23(t)
λ12(t)
λ14(t)
λ13(t)
λ34(t)
2: Response
1: Stable Disease 4: Death
3: Progression
In order to inform decision-making in early oncology drug development as described in Sec-
tion 1 not only based on response, but on OS predictions based on the above multistate model,
we have to derive the corresponding survival function for OS, SOS . This function will depend
on the transition hazards λij and/or the cumulative versions Λij , either directly or indirectly
through transition probabilities Pij , for i, j ∈ {1, . . . , 4}. Specifically,
SOS(t) = 1− P14(0, t)
= 1−
(
P1→4(0, t) + P1→3→4(0, t) + P1→2→4(0, t) + P1→2→3→4(0, t)
)
. (2)
The four terms P1→4, P1→3→4, P1→2→4, and P1→2→3→4 quantify the transition probabilities to
move from the initial State 1 to the death State 4, via all possible paths. The corresponding
formulas are derived in the appendix, and how to estimate SOS is discussed in Section 3.3.
3.3. Model assumptions
We will use a multistate model to compute a prediction of SOS for the patients recruited to
an early phase trial. In what follows, the characteristics of such an early phase trial are:
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i Single-arm trial with a modest number of patients, n. We assume throughout that
n = 40.
ii Limited follow-up for post-progression survival, as described below, making estimation
of the survival function for OS impractical.
In oncology, early development decisions are often based on this type of trials, potentially with
a different number of patients. In such trials, because an OS assessment is typically infeasible,
the focus traditionally lies on an assessment of response proportions. For immunotherapeutic
treatments, DOR also gained in popularity as an effect measure. Thus, information on the
transitions out of State 1 into States 2 and 3 (whether through State 2 or direct), and the
corresponding censoring information for patients remaining in State 1 or 2, is systematically
collected. This enables unbiased estimation of the transition hazards λ12, λ13, and λ23. The
transitions 1→ 4 and 2→ 4 rarely happen at all, and typically no relevant difference is seen
between arms. If they happen, the corresponding death dates are typically collected within
an early phase trial, because patients are generally followed-up until progression. As a result,
we get little, but completely collected event data to estimate these transition hazards. Since
these transitions are rare, the resulting transition probabilities are generally low, implying
that their contribution to the value of SOS is very limited.
For the transition hazard λ34, or post-progression hazard, data collection in early phase trials
is much less systematic, because protocol-specified follow-up generally ends after progression.
This implies that once a patient progresses, the information about a potential later death,
i.e. the 3 → 4 transition, and corresponding last-known alive dates are only anecdotically
known, at best. This makes estimation of λ34 challenging, if not impossible, at the time when
a decision needs to be taken whether to take a molecule forward into Phase 3. This, because -
as opposed to the transitions 1→ 4 and 2→ 4 where we collect little but (virtually) complete
data - we only observe a small proportion of the death events that actually happen after
progression.
So, instead of estimating the OS survival function of the experimental treatment we will
predict it based on the multistate model. To be able to do this, we need three ingredients:
i Historical data to inform the prediction, i.e. data sampled from a population that does
not systematically differ from the one the early phase trial is drawn from. Our case
studies below provide an idealized scenario for this: since all of them are pivotal RCTs,
we can simply use the control arm as our historical data. However, in a real-world
application of the proposed methodology, the historical control data will typically be
external to the early phase trial, implying a potential risk of selection or calendar time
bias. We will discuss this point further in Section 7.
ii The historical data needs to have (much) longer and more comprehensive survival follow-
up compared to the early phase trial. Again, the idealized scenario of using RCTs as
proof-of-concept provides this.
iii We need to make an assumption about the post-progression hazard functions in both
treatment arms. In Section 4 the one in the experimental arm will be completely bor-
rowed from the historical control whereas in Section 5, we will generalize this assumption
to the two post-progression hazards not being identical, but proportional.
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To compute SOS , in our case studies reported in Sections 4-6, we use cumulative hazard func-
tions predicted from Cox regressions, with a binary covariate for treatment arm. In contrast
to treatment-specific Nelson-Aalen estimates of the cumulative hazard for each transition,
this has the following advantages: it allows to receive predictions up to the last available ob-
servation (censored or event) in both treatment arms. As we will compare a historical control
arm with generally long-term follow-up to an experimental arm with much less follow-up,
having a predicted survival function up to the last observation in the control arm is helpful.
Furthermore, using Cox regression we either simply use an estimated baseline hazard from the
control arm (when assuming identical post-progression hazards in Section 4) or an estimate
based on the data of both arms (proportional post-progression hazards in Section 5), i.e. in
both cases we borrow strength from the control arm to make a prediction in the experimental
arm. Finally, using Cox regression to predict cumulative hazard functions also easily allows
for inclusion of (transition-specific) covariates. For the different transitions, we will keep the
model maximally flexible by assuming that each transition has its own baseline hazard.
So, within our multistate model framework, the hazard for a i → j transition for a subject
with a covariate vector Z is given by
λij(t |Z) = λij,0(t) · exp(βTijZ). (3)
Here, λij,0(t) is the baseline hazard for the considered transition and βij the vector of regression
coefficients. In the case studies in Sections 4-6 treatment information, i.e. whether a patient
belongs to the historical control or the experimental arm, will be the only covariate in our
transition-specific Cox models. As a consequence, βij describes the treatment effect on the
i→ j transition hazard. From a hazard function estimate λ̂ij(t |Z) we can then easily predict
the cumulative hazard function in both treatment arms, and these predictions are plugged-in
into (2) to get the overall survival function estimate.
Although we do not pursue this here when discussing early decision-making, further covari-
ates, even transition-specific, can be incorporated in the prediction of the cumulative hazard
functions.
Variability of SOS can be assessed as described in de Wreede, Fiocco, and Putter (2010).
4. OS prediction if post-progression hazards are assumed identical
Under the assumption of identical post-progression hazards in the control and the experi-
mental arm, the transition hazard λ34(t |Z) does not depend on the treatment covariate, i.e.
λ34(t |Z) = λ34(t) = λ34,0(t). Under this assumption, a prediction based on a multistate
model is simplified, and the post-progression information in the experimental arm can be
borrowed completely from the control arm.
The assumption of identical post-progression hazard is applicable when the treatments under
investigation are not expected to provide benefit beyond progression. Indeed, the chemother-
apy as well as ADCC mode of action work via a direct tumor cell killing mechanism. In both
cases, treatment will be stopped after a diagnosis of progression, the treatment does no longer
work and it seems reasonable that patients progressing at a same time will have similar tran-
sition hazards from progression to death, regardless of whether they received experimental or
control therapy.
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In Cleopatra, both arms belonged to the ADCC treatment class. In the following section,
we justify that the assumption of similar post-progression hazards is valid and illustrate that
the multistate model can predict long term survival of the experimental arm with limited
post-progression death events in the experimental arm. We first show that the multistate
model, based on the Cox model and with the assumption of equal post-progression hazards,
can reproduce the raw Kaplan-Meier (KM) estimates based on the full dataset. Second, we
show that the multistate model can provide a reliable prediction of the OS survival function
in the experimental arm when those patients who experience a post-progression death are
censored one day after their progression date (hence, the hazard estimation is solely based on
post-progression data from the control arm). Third, we explore operational characteristics of
an early development decision based on the predicted OS in a typical early phase setting via
simulating from the original data.
4.1. Analysis of the full dataset
Estimating the transition hazards in the multistate model described in Figure 1 using Cox
regression with treatment as a covariate yields the estimated hazard ratios in Table 1. The
number of events for each transition are reported in Table 5 in the appendix. The esti-
mated hazard ratio of the transition from progression into death amounts to 0.97, so that the
assumption of equal post-progression hazard functions therefore appears justified.
Table 1: Estimated transition hazard ratios from Cleopatra based on full dataset.
transition hazard ratio 95% CI p-value
1→ 2 1.16 [0.98, 1.37] 0.09
1→ 3 0.64 [0.47, 0.88] 0.006
1→ 4 0.66 [0.28, 1.55] 0.34
2→ 3 0.70 [0.55, 0.89] 0.0041
2→ 4 0.21 [0.06, 0.78] 0.02
3→ 4 0.97 [0.68, 1.37] 0.85
We can now predict the OS survival function in the experimental arm under the assumption
of common transition hazards from progression to death. Figure 2 displays the KM estimate
based on the original full dataset, the prediction based on the multistate model, also based
on the full dataset. We find that the multistate model-based prediction is accurate under the
assumption of proportional transition hazards and common transition hazard from progression
to death, i.e. the 3→ 4 transition.
4.2. Censoring of deaths immediately after progression in the experimental
arm
As a next step, we illustrate that the approach based on the multistate model is capable of
estimating the OS survival function, even if all post-PD events in the experimental arm are
censored one day after progression. In this case, the estimate of the transition hazard from
progression to death is based on data from the control arm only. The corresponding KM
estimate of the experimental arm is provided in Figure 2 (orange line). Including only deaths
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without progression illustrates the very limited OS information that enters the estimation of
the multistate model, see Table 5. Still, multistate models are able to accurately predict the
OS survival function, even in absence of post-progression data, the typical situation in early
phase clinical trials as described in Section 3.3. This is illustrated by the bold red line in
Figure 2.
Figure 2: Cleopatra: KM estimates and multistate (MS) predictions of SOS .
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4.3. Simulation of operating characteristics for an early phase trial
Finally, we want to assess whether the OS prediction of the experimental arm, based on
limited early data from this experimental arm and the post-progression hazard completely
from the control arm, indeed yields a decision rule with good operational characteristics. To
this end, the experimental arm in the Cleopatra trial represents data from the new molecule
to be tested in the early phase trial, and the control arm reflects the (historical) comparator
data. We mimic a typical early phase setting using simulation as follows:
1 In the control arm, all patients are used for estimation.
2a To mimic the experimental arm assuming the new drug does not work, an early phase
trial with 40 patients will be sampled with replacement from the control arm again.
This allows assessment of the false-positive rate.
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2b Assuming the experimental drug works as in Cleopatra, forty patients are sampled
with replacement from the Cleopatra experimental arm, in order to estimate the false-
negative rate.
In both, 2a and 2b, post-progression deaths for the sampled patients are censored im-
mediately after progression. SOS is then predicted for the 40 patients sampled from the
experimental arm, based on the multistate model and the full control arm.
3 The hazard ratio comparing experimental to control is approximated by fitting an ex-
ponential survival function to the predicted OS survival functions and taking the ratio
of estimated exponential hazard parameters.
4 Based on these hazard ratio estimates, we derive operating characteristics of a decision
defined as follows: a decision to further develop the experimental arm is made when
the observed hazard ratio is below a target value. These target values are chosen to be
0.8, 0.85, 0.9 and 1. Operating characteristics are estimated based on 1000 simulated
early phase trials of 40 patients by computing the proportion of simulations that yield a
hazard ratio above (false-negative) or below (false-positive) the considered target value.
In the simulations, recruitment was generated such that the 40 sampled patients were uni-
formly entering the trial during 6 months. The analysis is performed 9 months after the last
enrolled patient, such that the longest possible observation time is up to 15 months for the
first patient, and less for those recruited later. The follow up of 9 months after last patient
randomized was chosen based on the following consideration: median PFS time for the control
arm was about 12 months. To allow for enough time to collect a sufficient number of pro-
gression events in the experimental arm, even with a prolonged time to progression, follow-up
time was set to 15 months.
For illustration, the results of one simulation run when sampled from the experimental arm
are provided in Figure 3, with the first plot showing the KM estimate of the OS survival
function of the 40 early phase trial patients (solid) and the KM estimate of the experimental
arm survival function of Cleopatra (dashed). As expected, the early phase trial OS data
is immature and not able to provide a good estimate of the OS survival function. The
second plot again shows the estimated survival function from Cleopatra, now for the control
and experimental arm (black and red, respectively) in addition to the predicted OS survival
function for the experimental arm from the multistate model (solid red line), based on the
40 patients. We find that the multistate model prediction appears to be able to accurately
capture the shape of the Cleopatra experimental arm survival function. This illustrates how
the multistate model borrows information from the control arm for the estimation of the OS
survival function on the experimental arm.
Results of multistate OS estimation from the 1000 simulated early phase trials sampled from
the experimental (left) or control (right) Cleopatra arm are given in Figure 4. The false-
negative and false-positive rate of the decision rule defined above are given in Table 5. The
operating characteristics are favourable in an early phase trial setting in oncology, and illus-
trate the feasibility of a decision rule using a small trial with limited data (restricted follow
up and low number of post-progression deaths) based on a multistate model, where the tran-
sition from progression to death is borrowed from the historical control data. Furthermore,
operating characteristics are based on a prediction of OS, instead of response, whose quality
as a surrogate and relevance for the patient is often questionable, as discussed in Section 1.
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Figure 3: Results of one of 1000 simulated early phase trials of 40 patients, sampled from the
experimental arm.
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The mean HR over the 1000 simulated early phase trials amounts to 0.62 for the left table,
matching well the observed OS HR in Cleopatra (see Table 4). For the right table we get
0.99, again accurately reflecting the assumed scenario of no effect.
5. OS prediction if post-progression hazards are assumed proportional
Under the assumption of proportional post-progression hazard, the transition λ34(t |Z) de-
pends on the treatment covariate, i.e. λ34(t |Z) = λ34,0(t) exp(β34Z). The transition hazard
in the experimental arm is assumed to be proportional to the one in the control arm. Under
this assumption, the baseline hazard λ34,0(t) is estimated from both arms, and there should be
sufficient data on the experimental arm to allow estimation of β34. We address the question
of what sufficient data could mean in Section 6.
This assumption is plausible if the mode of action of the experimental arm is expected to
provide benefit beyond progression.The goal of cancer immunotherapy (CIT) is to boost or
restore the ability of the immune system to detect and destroy cancer cells by overcoming the
mechanisms by which tumors evade and suppress the immune response (Disis 2014). This
implies that the patient may still benefit of the treatment even after the disease progresses.
For this reason, in trials assessing CIT, often treatment beyond progression is allowed by the
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Figure 4: Multistate estimation of the OS survival function based on 1000 simulated early
phase trials of 40 patients (red lines) sampled from the experimental arm (left) and from the
control arm (right) and using the complete control arm from the Cleopatra trial. Black lines
represent the KM estimate of OS based on the full experimental (solid) and control (dashed)
arm.
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protocol in the CIT arm, as long as the investigator considers the treatment still to provide
clinical benefit.
Both the Imvigor211 and Oak trial compared a CIT to a chemotherapy. Given the mode
of action of the experimental treatment and the fact that treatment beyond progression was
allowed, the transition hazards from progression to death must be assumed to be different.
Rather than leaving the transition hazards from progression to death completely unspecified,
we assumed proportionality of these hazards between treatment arms. The benefit of this
approach is to borrow from the control some information on the shape of the transition
hazards. We show later that this assumption is plausible on both trials.
In this section, we replicate the investigations from Section 4 on the Imvigor211 and Oak data.
First, we assess the plausibility of the proportional post-progression hazards assumption on
the full dataset for both studies. Second, we show that the full dataset with limited follow
up allows to recover the HR for OS as observed on the full dataset. Third, we simulate early
phase trials with limited follow up and illustrate that the multistate model can be used for
decision making.
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Figure 5: table
False-negative and false-positive rate of multistate decision rule based on 1000 simulated
early phase trials of 40 patients sampled from the experimental (left) or control (right) arm
in Cleopatra.
False-negative rate
HR target value % HR > target value
0.80 0.16
0.85 0.11
0.90 0.07
1.00 0.04
0.80 0.16
False-positive rate
HR target value % HR < target value
0.80 0.21
0.85 0.29
0.90 0.39
1.00 0.55
0.80 0.21
5.1. Analysis of the full dataset for Imvigor211 and Oak
Tables 2 and 3 provide estimated hazard ratios for each transition for the two studies. Number
of events for each transition are reported in Tables 7 and 9 in the appendix. We find
evidence that the assumption of post-progression transition hazard functions being equal
appears unrealistic, unlike in Cleopatra discussed in Section 4. A statistical test that assesses
the null hypothesis of proportionality of hazards (Grambsch and Therneau 1994) gives p-
values of 0.78 and 0.93, respectively. The proportional hazards (PH) assumption for the
post-progression hazards thus appears reasonable in both studies.
Table 2: Estimated transition hazard ratios from Imvigor211 based on full dataset.
transition hazard ratio 95% CI p-value
1→ 2 1.22 [0.85, 1.73] 0.28
1→ 3 1.40 [1.19, 1.65] < 0.0001
1→ 4 0.95 [0.70, 1.29] 0.74
2→ 3 0.36 [0.21, 0.62] 0.00024
2→ 4 0.16 [0.03, 0.75] 0.02
3→ 4 0.72 [0.60, 0.85] 0.00019
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Table 3: Estimated transition hazard ratios from Oak based on full dataset.
transition hazard ratio 95% CI p-value
1→ 2 1.10 [0.76, 1.59] 0.61
1→ 3 1.28 [1.08, 1.51] 0.0046
1→ 4 0.58 [0.40, 0.84] 0.0041
2→ 3 0.39 [0.24, 0.65] 0.00028
2→ 4 0.16 [0.03, 0.79] 0.02
3→ 4 0.80 [0.66, 0.96] 0.02
5.2. Analysis on data with limited follow up
In this section, we confirm that the multistate model is able to provide a valid estimate for
the OS HR on data with limited follow up. In both trials, we censored the post-progression
death events that occurred later than 180 days after randomization in the experimental arm
of both studies. This corresponds to typical minimal follow up of early phase studies.
Figure 6 shows the following estimates of the OS survival function: The black line depicts
the KM estimate for the full dataset. The orange line is the KM estimate for OS of the
experimental arm, where all post-PD events after 180 days are censored at day 180 or at one
day after progression, whichever comes last. The green line is the OS prediction from a PH
model, where deaths in the experimental arm are censored if beyond 180 days after random-
ization. In this model, the baseline hazard was estimated from both experimental and control
arm, and the HR between the arms was used to derive the experimental OS survival function
estimate. Finally, the red line is the OS survival function prediction based on the multistate
model, taking all intermediate states into account. Especially in the Imvigor211 example, the
advantage of the multistate model becomes obvious. Only deaths before the separation of
the survival functions were available in the experimental arm, resulting in estimates of the
experimental OS survival function (green line) close to the survival function of the control
arm.
5.3. Operating Characteristics for Oak based on 1000 simulated early phase
trials of 40 patients
After illustrating that the proposed method allows to predict the OS survival function in the
experimental arm from our case studies, where the survival follow-up in the experimental
arm is limited but the post-progression hazards are different, we illustrate that the multistate
model is able to provide reliable OS estimates based on a dataset with limited sample size and
limited follow up in the experimental arm. Similarly to the Cleopatra case study in Section 4,
we simulate data and compute the operating characteristics for the Oak case study. Results
for Imvigor211 are deferred to the appendix.
The total trial duration was assumed to be 1 year, including a recruitment period of half a
year.
Figure 7 and Table 8 give the results. Despite a comparable response proportion in both
arms, simulation results show that the prediction and decision making based on a multistate
model based on limited sample size and follow up time is feasible and improves operational
characteristics compared to decision making solely based on response proportion. Again, the
average HRs over 1000 simulations are with values of 0.78 and 0.99, respectively, in line with
expectations (see Table 8).
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Figure 6: Estimation of the OS survival function in Imvigor211 (left) and Oak (right) when
death events are censored after 180 days after randomization (indicated through the vertical
line). The orange line is the survival function estimate of the experimental arm, where all
post-PD events after 180 days are administratively censored. The black lines depict the KM
estimates of OS on the full dataset for the control arm. The green line is the survival prediction
based on an estimated HR from a Cox regression model computed on both arms, and the red
line is the survival prediction based on the multistate model.
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Compared to the operating characteristics for Cleopatra in Table 5 we find that the false-
negative error is increased. This can be explained through the lower treatment effect, i.e. OS
HR, in Oak.
6. Minimum required survival follow-up for the experimental arm
When designing a new trial and if we do not just borrow the post-progression hazard from
the historical control data as in Section 4, the length of follow up for death events needs to be
determined to get a stable point estimate for the OS hazard ratio from the multistate model.
In this section, we analyse this question via simulation.
At the time of design of the early phase trial, we expect only the full individual patient data
for the reference control arm to be available. A multistate model can then be fitted to the
control data and with this model, new data can be generated assuming potential differences in
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Figure 7: Multistate estimation of the OS survival function from 1000 simulated early phase
trials of 40 patients (red lines) sampled from the experimental arm (left) and from the control
arm (right) and using the complete control arm from Oak trial. Black lines represents the
KM estimate of OS based on the full experimental (solid) and control (dashed) arms.
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the transition hazards for the experimental arm compared to the control. The hypothesized
HRs for each transition are to be determined based on the mechanism of action and its impact
on the different transitions, and on the expected efficacy of the new compound.
Using the Oak control arm as an example, we simulate experimental arm data where no
treatment effect is asssumed (i.e. HRs are set to 1) for all transitions, except for the ones
from response to progression and progression to death.
This would reflect the experience with studies comparing CITs with chemotherapy, where a
survival benefit was observed despite similar response proportions. In simulations, an identical
assumed hazard from SD to response will lead to similar percentage of responders between
both arms, the difference in the hazards from response to PD leads to a prolonged DOR, and
with the additional effect assumed for the post-progression hazard, the difference in the OS
survival functions can be tuned to become clinically meaningful.
The simulation study is then carried out as follows: First, the cumulative transition hazards
are estimated in the control arm. Second, we simulate 1000 early phase trials based on these
cumulative hazards and a hypothesized effect for each transition. For the hypothesis of an
active treatment, the transition HRs were assumed to be 0.3 and 0.6 for the response to PD
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Figure 8: table
False-negative and false-positive rate of multistate decision rule based on 1000 simulated early
phase trials of 40 patients sampled from the experimental (left) or control (right) arms in Oak.
False-Negative rate
HR target value % HR > target value
0.80 0.44
0.85 0.37
0.90 0.30
1.00 0.17
0.80 0.44
False-positive rate
HR target value % HR < target value
0.80 0.24
0.85 0.30
0.90 0.38
1.00 0.53
0.80 0.24
and post-progression transition, respectively, and 1 for all other transitions. This resulted in a
hazard ratio between experimental and control, averaged over the 1000 simulations, of 0.726,
a value close to the reported HR of the Oak trial. For the scenario of no treatment effect,
all transition hazards are set to 1. Third, we administratively censor the post-progression
transition after a given follow up time. This censoring time is denoted cut time and chosen
as 30, 60, 90, 120, 150, 180, 240, and 320 days after enrollment of the first patient. Only the
post-progression transition is cut, because all patients are typically followed up for response
and progression, as discussed in Section 3.3. For the patients that have transitioned to PD
after the cut time, the post-progression transition is administratively censored at the PD time
+ 1 day. For the patients that have transitioned to PD before the cut time, but are censored
or have an event after the cut time, the transition is administratively censored at the cut
time. These steps mimic the typical restriction on the follow up of patients in early phase
trials, where the follow up ends after progression. Fourth, we apply a new cut on the total
trial duration. As median PFS in Oak and Imvigor211 was around 4 months, the analysis
time was set to 6 month after last patient randomized, with recruitment assumed to be 1
year. This step is to mimic the situation in early development, where decisions about further
development steps have to be taken after a reasonable amount of data (especially response
and progression events) are accumulated. Fifth, we estimate the multistate model on the
modified simulated datasets and report the OS HR. The sample size of the simulated early
phase trial is again chosen to be 40.
Figure 9 reports the results. The average HR over the 1000 simulated early phase trials and a
95% confidence interval are displayed as a function of the cut time. The left plot assumes an
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active experimental arm and the right plot assumes no treatment effect. We observe for both
scenarios, i.e. when the experimental drug works as assumed above or does not work at all,
that after a follow up of ≥180 days enough information on deaths would have been collected
to get a sufficiently stable HR estimate. These results are comparable to a similar analysis
done by Huang, Das, Burger, Zhong, Zhang, and Lieberman (2014).
Figure 9: Oak, Estimate and 95% confidence interval for the OS HR as a function of the cut
time (time from randomization of patient to censoring of transition 6). Left: Active treatment
(Simulated HR = 0.3 and 0.6 for transitions 4 and 6, HR = 1 for other transitions). Right:
No treatment effect (HR = 1 for all transitions).
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An alternative could be to wait until a given number of events is obtained on the transition
from PD to death. However, this does not reflect the typical early phase trial situation, since
these trials generally do not specify an endpoint of OS, making it hard to justify a clinical
cutoff after a given number of death events. Typically, such trials fit in a development plan
that requires a read-out at a fixed calendar time.
7. Summary and Conclusion
A common way to evaluate the efficacy of a compound in an early phase trial in oncology is to
evaluate tumor response and progression. With the emergence of new therapies using different
mechanisms of action, this criteria may be less suitable to assess efficacy of a new therapy
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early. In addition, obtaining a reliable benchmark for the observed response proportion is
complicated by changing treatment paradigms, e.g. of treating beyond progression. As a
consequence, the link between the response proportion and the long-term Phase 3 endpoints
(like OS) gets even weaker.
In this paper, we illustrate that decision-making after an early phase trial in oncology devel-
opment can be considerably improved when not relying on differences in response rates only.
In the Imvigor211 and Oak case studies, the molecule would not have moved forward based
on a comparison of response rates.
Multistate models have been proposed earlier (see e.g. Broe¨t, de la Rochefordie`re, Scholl,
Fourquet, Rycke, Pouillart, Mosseri, and Asselain 1999; Putter, van der Hage, de Bock, El-
galta, and van de Velde 2006) to analyse the efficacy of oncology treatments, and to gain a
better understanding of the data. They are a natural way to take all transitions and transi-
tion times of a patient from trial entry to response, progression and/or death into account.
Interestingly, in our experience, these standard oncology endpoints are often analysed quite
independently of each other and not within a multistate framework. As we have shown, mul-
tistate models can be used to reliably predict survival differences, even in situations where
the difference in response proportions is small. In addition, the measure provided by the
multistate model, i.e. the OS HR, is more relevant to development programs and the patients
than response, as it is directly related to the typically used primary endpoint of subsequent
pivotal trials. Another advantage of multistate models is that it is straightforward to intro-
duce transition-dependent covariates. A potentially relevant covariate could e.g. be change in
tumor burden before progression as covariate for the post-progression transition. Exploring
these generalizations is subject of ongoing research.
We explore scenarios where the post-progression hazard is either assumed to be identical
between control and experimental arm, or proportional. Note that the post-progression, or
3→ 4, is only one of six transitions in our model described in Figure 1. It is not too difficult to
construct scenarios where all transitions have proportional hazards, but the resulting endpoint
OS does not. In other words, assuming PH for all transition probabilities may be a reasonable
assumption, as it may still give rise to a broad spectrum of overall survival functions that do
not necessarily need to have proportional hazards.
In all our analyses, we have assumed a sample size of 40 patients for the early phase trial.
As shown, this provides good operating characteristics for Cleopatra, in line with the quite
substantial effect size of a OS HR of 0.64. Operating characteristics were less impressive for
Oak and Imvigor211, because of their lower effect sizes. In the latter cases, one might want
to consider increasing the sample size of the early phase trial, and/or increase the follow-up,
in order to get more data to inform the OS prediction.
For our proposed method to work, one needs to be able to borrow from the control arm.
That borrowed data is ideally sampled from the same population as the early phase trial
itself, it must provide patient-individual information on response, progression, and death,
and it must have sufficient (survival) follow-up such that we can reliably estimate the post-
progression hazard function. The focus of our paper was to put the general concept to
test of using a multistate model to compute predictions of the OS survival function and
corresponding operating characteristics for an early phase decision. To make sure the control
and experimental arm were from the same population, we used both from RCTs and artificially
cut back the experimental arm data. This implies that calendar time and/or selection bias
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should not be present.
When prospectively applying the described multistate models to define early phase gating
criteria, the control data will likely come from a different source than the actually collected
experimental data from the early phase trial. One then needs to extend the proposed method-
ology such that the control and experimental arm populations are made suitably comparable,
e.g. through propensity score methods, see e.g. Austin (2011, 2014). These extensions are
subject of ongoing research.
8. Code and data
All analyses are performed using the mstate R package (R Core Team 2017, Putter et al.
2007).
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Appendix
A.1. Detailed results of case studies
Tables 4, 6, and 8 detail the efficacy outcomes reported in the primary publications of the
three case studies. Table 5, 7, and 9 provide the number of events for each transition of the
proposed multistate model.
Table 4: Cleopatra results, taken from Baselga et al. (2012) and Swain et al. (2015). Note
that Table 2 in Baselga et al. (2012) reports response proportions for patients with measurable
disease, while here proportions for all patients in Cleopatra are given.
Pertuzumab + Trastuzumab Trastuzumab HR (95% CI)
Survival N=402 N=406
Overall Survival 0.64 (0.47,0.88)
Progression-free Survival 0.62 (0.51,0.75)
Response N=343 N=336
Objective Response 275 (80.2%) 233 (69.3%)
Complete Response 19 (5.5%) 14 (4.2%)
Partial Response 256 (74.6%) 219 (65.2%)
Stable Disease 50 (14.6%) 70 (20.8%)
Progressive Disease 13 (3.8%) 28 (8.3%)
Not assessed/assessable 5 (1.5%) 5 (1.5%)
Duration of Response N=275 N=233
Median (months, 95% CI) 20.2 (16.0,24.0) 12.5 (10.0-15.0)
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Table 5: Cleopatra: Multistate model transition table.
Transition Pertuzumab + Trastuzumab Trastuzumab
From SD to Response 290 257
From SD to PD 63 98
From SD to Death 9 13
From Response to PD 130 138
From Response to Death 3 9
From PD to Death 57 74
Table 6: Imvigor211 results, taken from Powles et al. (2017).
Atezolizumab Chemotherapy HR (95% CI)
Survival N=467 N=464
Overall Survival 0.85 (0.73,0.99)
Progression-free Survival 1.1 (0.95,1.26)
Response N=462 N=461
Objective Response 62 (13.4%) 62 (13.4%)
Complete Response 13 (3%) 16 (3%)
Partial Response 46 (10%) 46 (10%)
Stable Disease 92 (20%) 162 (35%)
Progressive Disease 240 (52%) 150 (32%)
Not assessed/assessable 68 (15%) 87 (19%)
Duration of Response N=62 N=62
Median (months, 95% CI) 21.7 (13.0,21.7) 7.4 (6.1-10.3)
Table 7: Imvigor211: Multistate model transition table.
Transition Atezolizumab Chemotherapy
From SD to Response 62 62
From SD to PD 310 270
From SD to Death 74 91
From Response to PD 21 41
From Response to Death 2 8
From PD to Death 248 251
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Table 8: Oak results, taken from Rittmeyer et al. (2017).
Atezolizumab Chemotherapy HR (95% CI)
Survival N=425 N=425
Overall Survival 0.73 (0.62,0.87)
Progression-free Survival 0.95 (0.82,1.10)
Response N=425 N=425
Objective Response 58 (14%) 57 (13%)
Complete Response 6 (1%) 1 (<1%)
Partial Response 52 (12%) 56 (13%)
Stable Disease 150 (35%) 177 (42%)
Progressive Disease 187 (44%) 117 (28%)
Not assessed/assessable 30 (7%) 74 (17%)
Duration of Response N=58 N=57
Median (months, 95% CI) 26.3 (10,NE) 6.2 (4.9-7.6)
Table 9: Oak: Multistate model transition table.
Transition Atezolizumab Chemotherapy
From SD to Response 58 57
From SD to PD 306 249
From SD to Death 44 74
From Response to PD 26 40
From Response to Death 2 7
From PD to Death 224 212
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A.2. Derivation of transition probabilities in four-state multistate model
In this section we derive the four transition probabilities P1→4, P1→3→4, P1→2→4, and P1→2→3→4
that are used in Section 3.3 to define SOS .
In theory, to derive these transition probabilities one could follow the steps described e.g.
in Section A.2.5. of Aalen et al. (2008). This would entail writing down the transition
intensity matrix and then solve the Kolmogorov forward equations. However, the transition
probabilities can also be derived in an informal and intuitive way, see e.g. the paragraph
after Eq. (27) in Putter et al. (2007). As an example, to derive P1→4, i.e. the probability to
directly transition from State 1 to State 4, we can write
P1→4(0, t) =
∫ t
0
P11(0, u)λ14(u)P44(u, t)du. (4)
Here, P11(0, u) gives the probability to remain in State 1 from time 0 to s, then at u the
patient transitions to State 4 with intensity λ14(u), and finally has to remain in State 4 until
time t. Since State 4 in our model is absorbing, the latter probability is equal to 1, so that
we can simplify (4) to
P1→4(0, t) =
∫ t
0
exp
(
−Λ12(u)− Λ13(u)− Λ14(u)
)
λ14(u)du.
Eq. (5)-(10) can be derived similarly.
P1→3→4(0, t) =
∫ t
0
P11(0, u)λ13(u)P34(u, t)du
=
∫ t
0
exp
(
−Λ12(u)− Λ13(u)− Λ14(u)
)
λ13(u)×[
1− exp
(
−(Λ34(t)− Λ34(u))
)]
du, (5)
P1→2→4(0, t) =
∫ t
0
P11(0, u)λ12(u)P2→4(u, t)du
=
∫ t
0
exp
(
−Λ12(u)− Λ13(u)− Λ14(u)
)
λ12(u)P2→4(u, t)du, (6)
P1→2→3→4(0, t) =
∫ t
0
P11(0, u)λ12(u)P2→3→4(u, t)du
=
∫ t
0
exp
(
−Λ12(u)− Λ13(u)− Λ14(u)
)
λ12(u)P2→3→4(u, t)du, (7)
where
P11(0, t) = exp
(
−
∫ t
0
λ12(u) + λ13(u) + λ14(u)du
)
, (8)
P2→4(u, t) =
∫ t
u
exp
[
−
(
Λ23(v)− Λ23(u)
)
−
(
Λ24(v)− Λ24(u)
)]
λ24(v)dv, (9)
P2→3→4(u, t) =
∫ t
u
exp
[
−
(
Λ23(v)− Λ23(u)
)
−
(
Λ24(v)− Λ24(u)
)]
λ23(v)×[
1− exp
(
−(Λ34(v)− Λ34(u))
)]
dv (10)
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The overall transition probability P14(0, t) from the initial state at time 0 to the death state
at time t consists of the contributions of all possible paths from the initial to the death state,
namely directly (1→ 4), via the progressive state (1→ 3→ 4), or via the response state. In
the latter case, two further scenarios have to be considered, namely a direct transition into
death after response (1→ 2→ 4) or via an intermediate progressive event (1→ 2→ 3→ 4).
A.3. Operating characteristics of decision rule for the IMVigor211 trial.
In this section we present the operating characteristics of the decision rule based on simulations
from the Imvigor211 dataset. We note, as detailed in Table 6, that the observed OS HR for
this trial is 0.85, corresponding to a modest treatment effect. Therefore, it is not surprising
that the operating characteristics are inferior to those seen in Cleopatra and Oak. Figure 10
and Table 11 show the predicted survival functions and the proportion of false-negative (left
table) and false-positive (right table) decisions. The difference between the left and right
table shows the sensitivity of the proposed decision rule in absence of a difference in OR
proportion, and when the OS difference is small. These results further illustrate the usefulness
of the multistate model for decision making. For completeness, the average HRs over 1000
simulations are 0.90 for the left and 0.99 for the right table, respectively.
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Figure 11: table
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